EP Wealth Advisors LLC Invests $410,000 in IQVIA Holdings Inc. $IQV

EP Wealth Advisors LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, HoldingsChannel.com reports. The firm bought 2,122 shares of the medical research company’s stock, valued at approximately $410,000.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after purchasing an additional 159,899 shares in the last quarter. BlackRock Inc. acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $2,811,292,000. Geode Capital Management LLC grew its position in shares of IQVIA by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after purchasing an additional 24,453 shares in the last quarter. Boston Partners increased its holdings in shares of IQVIA by 14.9% during the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after purchasing an additional 530,672 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after buying an additional 528,753 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on IQV shares. Royal Bank Of Canada boosted their price target on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. lifted their price objective on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. HSBC reiterated a “buy” rating and set a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. TD Cowen boosted their price target on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. The trade was a 57.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock valued at $3,098,793 in the last quarter. Corporate insiders own 1.70% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $259.97 on Wednesday. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $261.88. The stock has a market capitalization of $42.79 billion, a price-to-earnings ratio of 32.25, a price-to-earnings-growth ratio of 2.21 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The company’s 50 day simple moving average is $216.59 and its 200 day simple moving average is $188.02.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s management believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.